NORTHWEST BIOTHERAPEUTICS INC (NWBO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 350K 700K 1.1M Q2 '16: 157K Q3 '16: 159K Q4 '16: 71K Q1 '17: 68K Q2 '17: 88K Q3 '17: 148K Q4 '17: 32K Q1 '18: 132K Q2 '18: 278K Q3 '18: 453K Q1 '19: 339K Q2 '19: 581K Q3 '19: 593K Q4 '19: 897K Q1 '20: 570K Q2 '20: 2K Q3 '20: 216K Q4 '20: 503K Q1 '21: 239K Q2 '21: 416K Q3 '21: 350K Q4 '21: 0 Q1 '22: 403K Q2 '22: 477K Q3 '22: 206K Q4 '22: 597K Q1 '23: 880K Q2 '23: 201K Q3 '23: 406K Q4 '23: 445K Q1 '24: 284K Q2 '24: 510K Q3 '24: 357K Q4 '24: 231K Q1 '25: 375K Q2 '25: 131K Q3 '25: 200K Q4 '25: 672K Q1 '26: 494K Q2 '26: 807K Q2 '17 Q3 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '16: -25.5M Q4 '16: -21.2M Q1 '17: -11.9M Q2 '17: -10.7M Q3 '17: -14.1M Q4 '17: -18M Q1 '18: -8.8M Q2 '18: -20.4M Q3 '18: -9.3M Q4 '18: -3M Q1 '19: -7.8M Q2 '19: -6.6M Q3 '19: -6.6M Q4 '19: -6.7M Q1 '20: -7.8M Q2 '20: -7.5M Q3 '20: -47.9M Q4 '20: -23.4M Q1 '21: -19.6M Q2 '21: -12.4M Q3 '21: -10M Q4 '21: -10.7M Q1 '22: -12.3M Q2 '22: -21.1M Q3 '22: -15.6M Q4 '22: -18.2M Q1 '23: -13M Q2 '23: -13.6M Q3 '23: -13.8M Q4 '23: -15.1M Q1 '24: -15.7M Q2 '24: -17.5M Q3 '24: -14.8M Q4 '24: -18.5M Q1 '25: -17.3M Q2 '25: -14.8M Q3 '25: -14.3M Q4 '25: -13.5M Q1 '26: -10.9M Q2 '26: -11.6M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-300M -200M -100M 0 100M 200M 300M Q3 '16: -29.2M Q4 '16: -30.7M Q1 '17: -12.6M Q2 '17: -10.3M Q3 '17: -23.3M Q4 '17: -27M Q1 '18: -21.5M Q2 '18: -21.2M Q3 '18: 12.6M Q4 '18: -5.7M Q1 '19: -20.9M Q2 '19: 219K Q3 '19: -6.4M Q4 '19: 6.3M Q1 '20: 2.6M Q2 '20: -58.1M Q3 '20: -194.1M Q4 '20: -280.3M Q1 '21: -4.1M Q2 '21: 4.4M Q3 '21: 45.5M Q4 '21: 133.3M Q1 '22: -14.2M Q2 '22: -29.7M Q3 '22: -32.9M Q4 '22: -28.3M Q1 '23: -10.7M Q2 '23: -14.4M Q3 '23: -23.5M Q4 '23: -14M Q1 '24: -18.3M Q2 '24: -17.9M Q3 '24: -19.4M Q4 '24: -28.2M Q1 '25: -19.3M Q2 '25: -15.4M Q3 '25: -26.8M Q4 '25: 1.4M Q1 '26: -3.1M Q2 '26: -9.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-21M -14M -7M 0 7M 14M 21M Q3 '16: 9.8M Q4 '16: -14.1M Q1 '17: -12.3M Q2 '17: -3.7M Q3 '17: -5.7M Q4 '17: -14.8M Q1 '18: -4.8M Q2 '18: -11.6M Q3 '18: -4.1M Q4 '18: -14.2M Q1 '19: -9.8M Q2 '19: -9.7M Q3 '19: -6.5M Q4 '19: -6M Q1 '20: -7.5M Q2 '20: -6.3M Q3 '20: -8M Q4 '20: -10.2M Q1 '21: -13.2M Q2 '21: -6.8M Q3 '21: -7M Q4 '21: -11.2M Q1 '22: -13M Q2 '22: -14.8M Q3 '22: -16.1M Q4 '22: -8.8M Q1 '23: -11.2M Q2 '23: -11.5M Q3 '23: -13.9M Q4 '23: -17M Q1 '24: -12.4M Q2 '24: -16.2M Q3 '24: -8.2M Q4 '24: -20.2M Q1 '25: -9.4M Q2 '25: -6.7M Q3 '25: -13.9M Q4 '25: -14.8M Q1 '26: -12.5M Q2 '26: -7.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q1 '13: -7.1M Q2 '13: -8.2M Q3 '13: -8M Q4 '13: -14.7M Q1 '14: -10.6M Q2 '14: -16.9M Q3 '14: -30.8M Q1 '15: -18.7M Q2 '15: -28M Q3 '15: 9.8M Q1 '19: -9.8M Q2 '19: -9.9M Q3 '19: -6.5M Q4 '19: -6.1M Q1 '20: -7.6M Q2 '20: -7.6M Q3 '20: -10.3M Q4 '20: -13.3M Q1 '21: -13.5M Q2 '21: -8.3M Q3 '21: -9.7M Q4 '21: -12.8M Q1 '22: -13M Q2 '22: -15.2M Q3 '22: -16.4M Q4 '22: -11M Q1 '23: -12.6M Q2 '23: -12.8M Q3 '23: -14.4M Q4 '23: -17.4M Q1 '24: -12.6M Q2 '24: -16.7M Q3 '24: -8.4M Q4 '24: -20.3M Q1 '25: -9.5M Q2 '25: -7M Q3 '25: -14.1M Q4 '25: -15.7M Q1 '26: -12.6M Q2 '26: -7.4M Q1 '14 Q3 '15 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 600M 1.2B 1.8B Q3 '10: 70.4M Q1 '11: 77.1M Q3 '11: 7.7K Q1 '12: 153.6M Q3 '12: 11K Q3 '14: 60.6M Q3 '15: 89.8M Q3 '16: 114.8M Q3 '17: 281.5M Q2 '18: 425K Q3 '18: 516.3K Q1 '19: 529.1K Q2 '19: 597.4K Q3 '19: 577.1K Q1 '20: 648.9K Q2 '20: 697.6K Q3 '20: 747.7K Q1 '21: 834.6K Q2 '21: 1.2M Q3 '21: 1.1M Q1 '22: 959.3K Q2 '22: 1M Q3 '22: 1M Q1 '23: 1.1M Q2 '23: 1.1M Q3 '23: 1.1M Q1 '24: 1.2M Q2 '24: 1.2M Q3 '24: 1.3M Q1 '25: 1.4B Q2 '25: 1.4B Q3 '25: 1.5M Q1 '26: 1.6B Q2 '26: 1.6B Q1 '12 Q3 '17 Q3 '19 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q4 '10: -0.41 Q1 '11: -0.43 Q2 '11: -0.44 Q3 '13: -3.72 Q4 '13: -1.99 Q1 '14: -2.33 Q2 '14: -2.38 Q3 '14: -2.08 Q4 '14: -2.32 Q1 '15: -2.11 Q2 '15: -2.54 Q3 '15: -1.94 Q4 '15: -1.57 Q1 '16: -0.96 Q2 '16: -0.24 Q3 '16: -0.77 Q4 '16: -0.75 Q1 '17: -0.77 Q2 '17: -0.66 Q3 '17: -0.46 Q4 '17: -0.31 Q1 '18: -0.32 Q4 '10 Q3 '13 Q2 '14 Q1 '15 Q4 '15 Q3 '16 Q2 '17 Q1 '18

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.